With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
The plan is to advance innovative therapies to drug-resistant cancers
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
Formula attenuates 99% of 365 coronaviruses in computer models
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Subscribe To Our Newsletter & Stay Updated
